Biocartis inks breast cancer R&D deal Belgian diagnostics company Biocartis Group NV and Singpores A*STAR ETPL have kicked off development of a multimodal breast cancer assay designed to guide therapy selection in personalised medici … more ➔
4SC AG raises €41m Small molecule cancer drug developer 4SC AG (Planegg-Martinsried, Germany) has completed a capital increase fueling development of its clinical programmes for resminostat, 4SC-202 and 4SC-208 more ➔
Success for individualised cancer vaccineGerman biotech company Biontech AG has published positive clinical results for its individualised cancer vaccine Ivac mutanome in patients with late-stage melanoma. more ➔
Seventure debuts in Japan with microbiome... Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life … more ➔
Noxxon/MSD start testing of immunoncologic...Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off … more ➔
Exscientia inks €37m contract with GSKBritish pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)s artificial intelligence (AI)-driven drug discovery platform. more ➔
Breaking therapy resistance of follicular...Swiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy. more ➔
AML: Cellectis testing allogenic CAR-T cel... Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia. more ➔
Diabetes: J&J and Seventure Partners...European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, … more ➔
€66m Life Sciences Fund focused on Germa...Venture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Banks InnovFin Equity Facility and the Dutch … more ➔
